IL149487A0 - Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same - Google Patents

Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL149487A0
IL149487A0 IL14948700A IL14948700A IL149487A0 IL 149487 A0 IL149487 A0 IL 149487A0 IL 14948700 A IL14948700 A IL 14948700A IL 14948700 A IL14948700 A IL 14948700A IL 149487 A0 IL149487 A0 IL 149487A0
Authority
IL
Israel
Prior art keywords
polycycloalkylpurine
derivatives
same
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL14948700A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL149487A0 publication Critical patent/IL149487A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL14948700A 1999-11-12 2000-11-13 Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same IL149487A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16519199P 1999-11-12 1999-11-12
PCT/US2000/031058 WO2001034610A1 (en) 1999-11-12 2000-11-13 Polycycloalkylpurines as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
IL149487A0 true IL149487A0 (en) 2002-11-10

Family

ID=22597852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14948700A IL149487A0 (en) 1999-11-12 2000-11-13 Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same

Country Status (35)

Country Link
US (5) US6649600B1 (pt)
EP (3) EP1230243B1 (pt)
JP (1) JP2003513982A (pt)
KR (2) KR100863761B1 (pt)
CN (2) CN100390178C (pt)
AT (1) ATE424403T1 (pt)
AU (1) AU784556B2 (pt)
BG (1) BG65720B1 (pt)
BR (1) BR0015545A (pt)
CA (1) CA2390496A1 (pt)
CY (1) CY1110512T1 (pt)
CZ (1) CZ20021614A3 (pt)
DE (1) DE60041710D1 (pt)
DK (1) DK1230243T3 (pt)
EA (1) EA005211B1 (pt)
EE (1) EE05365B1 (pt)
ES (1) ES2323357T3 (pt)
GE (1) GEP20043303B (pt)
HK (1) HK1049155B (pt)
IL (1) IL149487A0 (pt)
IS (1) IS6379A (pt)
ME (1) MEP42208A (pt)
MX (1) MXPA02004796A (pt)
NO (1) NO328956B1 (pt)
NZ (2) NZ527917A (pt)
PL (1) PL206890B1 (pt)
PT (1) PT1230243E (pt)
RS (1) RS50381B (pt)
SI (1) SI1230243T1 (pt)
SK (1) SK287311B6 (pt)
TR (1) TR200201260T2 (pt)
TW (1) TWI272270B (pt)
UA (1) UA77391C2 (pt)
WO (1) WO2001034610A1 (pt)
ZA (1) ZA200203701B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004795A (es) * 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE10145193C1 (de) 2001-09-13 2003-03-13 Sachtler Gmbh & Co Kg Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
EA200500005A1 (ru) * 2002-06-12 2005-06-30 Байоджен Айдек Ма Инк. Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es) * 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
CA2528385C (en) 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
CN101248041B (zh) 2005-06-17 2013-11-20 艾宝奇生物工艺有限公司 鞘氨醇激酶抑制剂
WO2007059330A2 (en) * 2005-11-17 2007-05-24 Medkura Inc. Cubane nucleoside analogs
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101085785B (zh) * 2006-06-06 2011-09-21 中国科学院上海药物研究所 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8685471B2 (en) * 2006-07-17 2014-04-01 Tyratech, Inc. Compositions and methods for controlling insects
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
CA2709772A1 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en) 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
CA2782629A1 (en) * 2009-12-04 2011-06-09 Commonwealth Scientific And Industrial Research Organisation Polymeric materials
CN101709034B (zh) * 2009-12-14 2017-05-31 大连九信精细化工有限公司 双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
TWI538905B (zh) * 2010-12-22 2016-06-21 Ｈ 朗德貝克公司 雙環［３．２．１］辛基醯胺衍生物及其用途
US20140243302A1 (en) 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
EP2970172B1 (en) * 2013-03-14 2019-10-30 Bristol-Myers Squibb Company Bicyclo [2.2.2]acid gpr120 modulators
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
CN109843846B (zh) 2016-10-19 2022-07-05 伊士曼化工公司 双环[2.2.2]辛烷的合成
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
US11518726B2 (en) 2017-10-11 2022-12-06 Eastman Chemical Company Synthesis of bicyclo[2.2.2]octane derivatives
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
US10836899B2 (en) 2018-12-13 2020-11-17 Eastman Chemical Company Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011399A1 (en) * 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
ES2152207T3 (es) 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
JPH04270222A (ja) * 1991-02-25 1992-09-25 Kyowa Hakko Kogyo Co Ltd 脳機能改善剤
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
JPH04346986A (ja) * 1991-05-23 1992-12-02 Kyowa Hakko Kogyo Co Ltd トリチウム標識化されたキサンチン誘導体
JP3115128B2 (ja) * 1991-11-08 2000-12-04 協和醗酵工業株式会社 キサンチン誘導体
EP0541120B1 (en) 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH0616668A (ja) * 1992-03-12 1994-01-25 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
TW252044B (pt) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5384176A (en) * 1992-12-11 1995-01-24 Zimmerman; Richard C. Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057644A1 (en) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Preventive and remedy for drug-induced nephropathy
WO1998057645A1 (en) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Hepatic edema remedy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE252905T1 (de) 1998-04-24 2003-11-15 Biogen Inc Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
EP1092435B1 (en) 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
MXPA02004795A (es) * 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
DE60304911D1 (de) * 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物

Also Published As

Publication number Publication date
CN100390178C (zh) 2008-05-28
US20090221821A1 (en) 2009-09-03
CN1402729A (zh) 2003-03-12
PL206890B1 (pl) 2010-10-29
CZ20021614A3 (cs) 2002-07-17
US20070015732A1 (en) 2007-01-18
TR200201260T2 (tr) 2002-09-23
EE200200247A (et) 2003-06-16
TWI272270B (en) 2007-02-01
NZ527917A (en) 2005-03-24
AU1600001A (en) 2001-06-06
BG65720B1 (bg) 2009-08-31
HK1049155A1 (en) 2003-05-02
CA2390496A1 (en) 2001-05-17
PL356033A1 (en) 2004-06-14
CN101255162A (zh) 2008-09-03
HK1049155B (en) 2009-11-06
RS50381B (sr) 2009-11-10
KR20020049050A (ko) 2002-06-24
YU33802A (sh) 2006-01-16
US6649600B1 (en) 2003-11-18
US7579354B2 (en) 2009-08-25
MXPA02004796A (es) 2007-01-30
NO20022238L (no) 2002-07-12
BG106762A (en) 2003-01-31
US20040067966A1 (en) 2004-04-08
SK287311B6 (sk) 2010-06-07
US20060252730A1 (en) 2006-11-09
DK1230243T3 (da) 2009-06-15
CY1110512T1 (el) 2015-04-29
AU784556B2 (en) 2006-05-04
MEP42208A (en) 2011-02-10
PT1230243E (pt) 2009-06-12
SK6632002A3 (en) 2003-02-04
EP2070930A1 (en) 2009-06-17
EA200200560A1 (ru) 2002-10-31
KR100863761B1 (ko) 2008-10-16
EA005211B1 (ru) 2004-12-30
DE60041710D1 (de) 2009-04-16
SI1230243T1 (sl) 2009-08-31
NO20022238D0 (no) 2002-05-10
ATE424403T1 (de) 2009-03-15
ZA200203701B (en) 2004-02-23
KR20080027971A (ko) 2008-03-28
IS6379A (is) 2002-05-10
EP1230243B1 (en) 2009-03-04
GEP20043303B (en) 2004-01-12
BR0015545A (pt) 2002-08-06
EP2305684A1 (en) 2011-04-06
UA77391C2 (en) 2006-12-15
EP1230243A1 (en) 2002-08-14
WO2001034610A1 (en) 2001-05-17
NO328956B1 (no) 2010-06-28
NZ519426A (en) 2003-08-29
EE05365B1 (et) 2010-12-15
JP2003513982A (ja) 2003-04-15
ES2323357T3 (es) 2009-07-14

Similar Documents

Publication Publication Date Title
IL149487A0 (en) Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same
IL149486A0 (en) Purine derivatives and pharmaceutical compositions containing the same
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
WO1999002502A3 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
HUT61022A (en) Process for producing 8-substituted purine derivatives functioning as selective adenosine receptor, as well as pharmaceutical compositions comprising same as active ingredient
CA2094703A1 (en) Substituted piperazines as central nervous system agents
GB9601722D0 (en) Heterocyclic derivatives
EP1167353A4 (en) MORPHINE DERIVATIVES OR SALTS THEREOF AND MEDICAL COMPOSITIONS CONTAINING THEM
UA27738C2 (uk) 2,3,4,5,6,7-гексагідро-1-[4-[1-[4-(2метоксифеніл)піперазиніл]]-2-фенілбутирил]-1н-азепін або його фармацевтично прийнятна кислотно-адитивна сіль, що мають властивість пов'язувати рецептор 5нт1а, спосіб (варіанти) їх одержання, фармацевтична композиція

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees